Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Treason trial of South Sudan's suspended VP is further eroding peace deal, UN experts say - 2Computerized Domains d: A Survey of \Vivid Undertakings\ Computer generated Reality Game
- 3Aspirin can prevent a serious pregnancy complication — but too few women get it, new report suggests
- 4Fundamental Home Machines: An Easy to understand Determination Guide
- 5Instructions to Safeguard Your Speculations In the midst of Changing Disc Rates
- Steven Spielberg's 'Disclosure Day' trailer drops: What we know about the alien movie
- Nestlé recalls infant formula in 49 countries. See list.
- Drones haven't won the fight in Ukraine. That matters as the West learns new ways of war.
- Figure out How to Track the Establishment of New 5G Pinnacles
- Africa's energy giants eye long-term gains on Iran war disruption
- 2 of Earth's rarest lightning phenomena captured simultaneously in once-in-a-lifetime photo
- What to expect from the planets in 2026 — key dates and sky events
- Figure out How to Streamline Eco-friendliness in Your Volvo XC40
- CDC vaccine panel votes to remove universal hepatitis B birth dose recommendation
